Home > Research > Publications & Outputs > RNA-binding proteins in vascular inflammation a...

Links

Text available via DOI:

View graph of relations

RNA-binding proteins in vascular inflammation and atherosclerosis

Research output: Contribution to Journal/MagazineReview articlepeer-review

Published

Standard

RNA-binding proteins in vascular inflammation and atherosclerosis. / Sachse, Marco; Tual-Chalot, Simon; Ciliberti, Giorgia et al.
In: Atherosclerosis, Vol. 374, 30.06.2023, p. 55-73.

Research output: Contribution to Journal/MagazineReview articlepeer-review

Harvard

Sachse, M, Tual-Chalot, S, Ciliberti, G, Amponsah-Offeh, M, Stamatelopoulos, K, Gatsiou, A & Stellos, K 2023, 'RNA-binding proteins in vascular inflammation and atherosclerosis', Atherosclerosis, vol. 374, pp. 55-73. https://doi.org/10.1016/j.atherosclerosis.2023.01.008

APA

Sachse, M., Tual-Chalot, S., Ciliberti, G., Amponsah-Offeh, M., Stamatelopoulos, K., Gatsiou, A., & Stellos, K. (2023). RNA-binding proteins in vascular inflammation and atherosclerosis. Atherosclerosis, 374, 55-73. https://doi.org/10.1016/j.atherosclerosis.2023.01.008

Vancouver

Sachse M, Tual-Chalot S, Ciliberti G, Amponsah-Offeh M, Stamatelopoulos K, Gatsiou A et al. RNA-binding proteins in vascular inflammation and atherosclerosis. Atherosclerosis. 2023 Jun 30;374:55-73. Epub 2023 Jun 15. doi: 10.1016/j.atherosclerosis.2023.01.008

Author

Sachse, Marco ; Tual-Chalot, Simon ; Ciliberti, Giorgia et al. / RNA-binding proteins in vascular inflammation and atherosclerosis. In: Atherosclerosis. 2023 ; Vol. 374. pp. 55-73.

Bibtex

@article{94e46dad331d4098afbbdbbc063b6ded,
title = "RNA-binding proteins in vascular inflammation and atherosclerosis",
abstract = "Atherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability worldwide, even when patients with an established manifestation of atherosclerotic heart disease are optimally treated according to the clinical guidelines. Apart from the epigenetic control of transcription of the genetic information to messenger RNAs (mRNAs), gene expression is tightly controlled at the post-transcriptional level before the initiation of translation. Although mRNAs are traditionally perceived as the messenger molecules that bring genetic information from the nuclear DNA to the cytoplasmic ribosomes for protein synthesis, emerging evidence suggests that processes controlling RNA metabolism, driven by RNA-binding proteins (RBPs), affect cellular function in health and disease. Over the recent years, vascular endothelial cell, smooth muscle cell and immune cell RBPs have emerged as key co- or post-transcriptional regulators of several genes related to vascular inflammation and atherosclerosis. In this review, we provide an overview of cell-specific function of RNA-binding proteins involved in all stages of ASCVD and how this knowledge may be used for the development of novel precision medicine therapeutics.",
keywords = "Humans, Atherosclerosis/genetics, RNA-Binding Proteins/genetics, Inflammation/genetics",
author = "Marco Sachse and Simon Tual-Chalot and Giorgia Ciliberti and Michael Amponsah-Offeh and Kimon Stamatelopoulos and Aikaterini Gatsiou and Konstantinos Stellos",
year = "2023",
month = jun,
day = "30",
doi = "10.1016/j.atherosclerosis.2023.01.008",
language = "English",
volume = "374",
pages = "55--73",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - RNA-binding proteins in vascular inflammation and atherosclerosis

AU - Sachse, Marco

AU - Tual-Chalot, Simon

AU - Ciliberti, Giorgia

AU - Amponsah-Offeh, Michael

AU - Stamatelopoulos, Kimon

AU - Gatsiou, Aikaterini

AU - Stellos, Konstantinos

PY - 2023/6/30

Y1 - 2023/6/30

N2 - Atherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability worldwide, even when patients with an established manifestation of atherosclerotic heart disease are optimally treated according to the clinical guidelines. Apart from the epigenetic control of transcription of the genetic information to messenger RNAs (mRNAs), gene expression is tightly controlled at the post-transcriptional level before the initiation of translation. Although mRNAs are traditionally perceived as the messenger molecules that bring genetic information from the nuclear DNA to the cytoplasmic ribosomes for protein synthesis, emerging evidence suggests that processes controlling RNA metabolism, driven by RNA-binding proteins (RBPs), affect cellular function in health and disease. Over the recent years, vascular endothelial cell, smooth muscle cell and immune cell RBPs have emerged as key co- or post-transcriptional regulators of several genes related to vascular inflammation and atherosclerosis. In this review, we provide an overview of cell-specific function of RNA-binding proteins involved in all stages of ASCVD and how this knowledge may be used for the development of novel precision medicine therapeutics.

AB - Atherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability worldwide, even when patients with an established manifestation of atherosclerotic heart disease are optimally treated according to the clinical guidelines. Apart from the epigenetic control of transcription of the genetic information to messenger RNAs (mRNAs), gene expression is tightly controlled at the post-transcriptional level before the initiation of translation. Although mRNAs are traditionally perceived as the messenger molecules that bring genetic information from the nuclear DNA to the cytoplasmic ribosomes for protein synthesis, emerging evidence suggests that processes controlling RNA metabolism, driven by RNA-binding proteins (RBPs), affect cellular function in health and disease. Over the recent years, vascular endothelial cell, smooth muscle cell and immune cell RBPs have emerged as key co- or post-transcriptional regulators of several genes related to vascular inflammation and atherosclerosis. In this review, we provide an overview of cell-specific function of RNA-binding proteins involved in all stages of ASCVD and how this knowledge may be used for the development of novel precision medicine therapeutics.

KW - Humans

KW - Atherosclerosis/genetics

KW - RNA-Binding Proteins/genetics

KW - Inflammation/genetics

U2 - 10.1016/j.atherosclerosis.2023.01.008

DO - 10.1016/j.atherosclerosis.2023.01.008

M3 - Review article

C2 - 36759270

VL - 374

SP - 55

EP - 73

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -